A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

Lupus

Volumn 17, Issue 7, 2008, Pages 622-629

  Lu, F ^a   Tu, Y ^a   Peng, X ^a   Wang, L ^a   Wang, H ^a   Sun, Z ^a   Zheng, H ^a   Hu, Z ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Induction treatment; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; SERUM ALBUMIN;

ADD ON THERAPY; ARTICLE; BACTERIAL INFECTION; CAUSE OF DEATH; CHINESE; CHRONICITY; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; LABORATORY TEST; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; REMISSION; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; BIOPSY; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 48249117559     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308089428     Document Type: Article

References (22)

1. Chan, TM. Lupus nephritis: induction therapy. Lupus 2005; 14: 1-6.
2. Bono, L, Cameron, JS, Hicks, JA. The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med 1999; 92: 211-218.
3. Levey, AS, Lan, SP, Corwin, HL, et al. Progression and remission of renal disease in the lupus nephritis collaborative study. Ann Intern Med 1992; 116: 114-123.
4. Donadio, JV, Holley, KE, Ferguson, RH, Ilstrup, DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151-1155.
5. Illei, GG, Austin, HA, Grane, M, et al. Combination therapy with pulse cyclophosphamide plus pulse methyprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
6. Steinberg, AD, Steinberg, SC. Long-term preservation of renal functions in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945-950.
7. Allsion, AC, Eugui, EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84.
8. Halloran, P, Mathew, T, Tomlanovich, S, Groth, C, Hooftman, L, Barker, C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39-47.
9. [Erratum, Transplantation 1997; 63: 618]
10. Chan, TM, Li, FK, Tang, CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
11. Chan, TM, Tse, KC, Li, FK, et al. Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
12. Ginzler, EM, Dooley, MA, Aranow, C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
13. Li, RS, Wang, HY, Lin, SY, et al. A multi-centre study of mycophenolate mofetil for diffuse proliferative lupus nephritis. Chinese J Inter Med 2002; 41: 476-479.
14. Contreras, G, Pardo, V, Leclercq, B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
15. Donadio, JV. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Transplant 1992; 7(Suppl. 1): 97-104.
16. Sloan, RP, Schwartz, MM, Korbet, SM, et al. ; The Lupus Nephritis Collaborative Study Group. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 1996; 7: 299-305.
17. Balow, JE, Austin, HA. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003; 23: 386-391.
18. Schwartz, MM, Lan, SP, Bonsib, SM, et al. Chronic outcome of three discrete histiologic patterns of injury in severe lupus nephritis. Am J Kidney Dis 1989; 13: 273-283.
19. Chan, TM, Li, FK, Wong, RW, Wong, KL. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-327.
20. Pisoni, CN, Sanchez, FJ, Karim, Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052.
21. Lee, HS, Mujais, SK, Kasinath, BS, et al. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984; 77: 612-620.
22. Hill, GS. Systemic lupus erythematosus. In: Heptinstall, RH, (ed), Pathology of kidney. 4th ed. Boston: Little Brown; 1992. p. 871.